4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Peapod Lane Capital LLC

Peapod Lane Capital LLC cut its holdings in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 16.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 268,024 shares of the company’s stock after selling 54,057 shares during the period. 4D Molecular Therapeutics comprises about 1.7% of Peapod Lane Capital LLC’s investment portfolio, making the stock its 25th biggest holding. Peapod Lane Capital LLC owned approximately 0.47% of 4D Molecular Therapeutics worth $2,010,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Wexford Capital LP acquired a new stake in shares of 4D Molecular Therapeutics during the third quarter valued at about $41,000. Farther Finance Advisors LLC grew its stake in shares of 4D Molecular Therapeutics by 117.4% during the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after acquiring an additional 2,674 shares in the last quarter. Abich Financial Wealth Management LLC acquired a new stake in shares of 4D Molecular Therapeutics during the third quarter valued at about $80,000. Inscription Capital LLC acquired a new stake in shares of 4D Molecular Therapeutics during the third quarter valued at about $94,000. Finally, Impact Partnership Wealth LLC acquired a new position in 4D Molecular Therapeutics in the third quarter worth about $96,000. 99.27% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

FDMT has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Monday. Barclays initiated coverage on 4D Molecular Therapeutics in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $33.00 price target for the company. Jefferies Financial Group reiterated a “buy” rating and issued a $21.00 price target (down from $40.00) on shares of 4D Molecular Therapeutics in a research note on Monday, March 30th. Finally, Royal Bank Of Canada lifted their price target on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the stock an “outperform” rating in a research note on Thursday, March 19th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $31.25.

4D Molecular Therapeutics Trading Down 1.9%

FDMT opened at $9.61 on Friday. The business’s 50 day moving average is $9.37 and its 200-day moving average is $9.49. The stock has a market cap of $490.59 million, a PE ratio of -3.97 and a beta of 2.94. 4D Molecular Therapeutics, Inc. has a twelve month low of $3.00 and a twelve month high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings results on Wednesday, March 18th. The company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.96. The company had revenue of $85.09 million for the quarter, compared to analysts’ expectations of $30.86 million. 4D Molecular Therapeutics had a negative return on equity of 31.75% and a negative net margin of 164.43%. As a group, analysts forecast that 4D Molecular Therapeutics, Inc. will post -3.71 EPS for the current year.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.